Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4Rα, for the treatment of Th2 inflammatory diseases
Used in this study: B-hIL4/hIL4RA Mice
Read entire articleUsed in this study: B-hIL4/hIL4RA Mice
Read entire article